Rucaparib

5 trials 2 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

14 Countries

Phase III

Phase II

Phase III: 1 Phase II: 4

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Fallopian tube cancer 3 Malignant peritoneal neoplasm 2 Ovarian cancer recurrent 1 Ovarian cancer metastatic 1 Fallopian tube cancer metastatic 1 Ovarian epithelial cancer 1

Sponsors using this IMP

AGO Research GmbH 1 Bristol-Myers Squibb Services Unlimited Company 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 pharmaand GmbH 1

All trials

5 total

Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 Phase II 1 country AGO Research GmbH
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas… Ended

2024-516662-11-00 Phase III 11 countries pharmaand GmbH

Showing 1–5 of 5 trials

← All drugs A–Z